Orexigen Therapeutics, Inc
Quick facts
Marketed products
- NB · Obesity / Metabolic Disease
NB (naltrexone/bupropion) is a combination drug that reduces appetite and increases energy expenditure through opioid antagonism and norepinephrine/dopamine reuptake inhibition.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: